On behalf of ASPET’s Board of Publications Trustees, I am pleased to announce that Dr. Kathryn E. Meier has been selected to succeed Dr. Stephen F. Traynelis as the next Editor of Molecular Pharmacology. Dr. Meier will fully assume the editorship in January 2017 when Dr. Traynelis’ term will end. Dr. Meier’s appointment as editor culminates a selection process that began in March of this year.
Dr. Meier received the B.A. degree in biology, cum laude, from the University of California, San Diego, and the Ph.D. degree in pharmacology from the University of Wisconsin, Madison. She was an NIH predoctoral trainee with the Department of Pharmacology, School of Medicine, University of Wisconsin and an NIH postdoctoral fellow in the Division of Pharmacology, Department of Medicine, University of California, San Diego, where Dr. Paul Insel was her mentor.
She has held positions with the Howard Hughes Medical Institute in the Department of Pharmacology, University of Washington, and with the Department of Cell and Molecular Pharmacology and Experimental Therapeutics and the Hollings Cancer Center at the Medical University of South Carolina. Since 2003, she has been with Washington State University in the Department of Pharmaceutical Sciences (professor), where she has held several administrative positions (chair, Pharmaceutical Sciences; interim assistant dean for curriculum and research affairs; director, Program in Nutrition and Exercise Physiology). Since 2013, Dr. Meier has been associate dean for graduate education for the College of Pharmacy at Washington State University.
Dr. Meier’s laboratory studies the molecular pharmacology of signal transduction, with a recent focus on GPCR receptor-mediated mechanisms by which omega-3 fatty acids inhibit the growth of certain cancers. Her research has generated over 80 articles and book chapters and nearly 100 published abstracts.
Dr. Meier has served as an associate editor for The Journal of Pharmacology and Experimental Therapeutics since 2012. She has served or currently serves on the editorial boards of Journal of Biological Chemistry, American Journal of Physiology (Cell Physiology), and Molecular Pharmacology. In addition, Dr. Meier has been a reviewer for 27 journals in the areas of pharmacology, cancer, biochemistry, pathology, nutrition, and related fields.
Dr. Meier has served on over 20 review boards for the NIH, the National Science Foundation, the Department of Defense, the Veteran’s Administration, and other research and funding organizations in the U.S. and abroad.
Dr. Meier has been an ASPET member since 1994. She has been a member of the Molecular Pharmacology Division, serving as secretary/treasurer, and was a member of the Short Course/Continuing Education Committee. Dr. Meier will complete her term on ASPET’s Board of Publications Trustees at the end of 2016. She has served as the ASPET representative to the FASEB Publications and Communications Committee. She is also a member of the American Association for the Advancement of Science and the American Physiological Society.
Prospective Molecular Pharmacology authors should note that the manuscript submission process will not change with the change in editors. All submissions will continue to be handled through the journal’s online manuscript system (submit-molpharm.aspetjournals.org).
The Board of Publications Trustees is very pleased that Dr. Meier has accepted the editorship of Molecular Pharmacology and looks forward to the continued success of the journal under her leadership.
Footnotes
- Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics